Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results